| 1. |
Blaszczyk B, Lasoń W, Czuczwar SJ.Antiepileptic drugs and adverse skin reactions:An update.Pharmacological Reports, 2015, 67(3):426-434.
|
| 2. |
Ye YM, Thong BYH, Park HS.Hypersensitivity to antiepileptic drugs.Immunology and Allergy Clinics of North America, 2014, 34(3):633-643.
|
| 3. |
Ari fH, Buchsbaum R, Weintraub D, et al.Comparison and predictors of rash associated with 15 antiepileptic drugs.Neurology, 2007, 68(20):1701-1709.
|
| 4. |
Bohan KH, Mansuri TF, Wilson NM.Anticonvulsant hypersensitivity syndrome:Implications for pharmaceutical care.Pharmacotherapy, 2007, 27(10):1425-1439.
|
| 5. |
袁靜.中毒性表皮壞死松解癥和Stevens-Johnson綜合征.實用醫院臨床雜志, 2012, 9(4):207-209.
|
| 6. |
常小龍, 譚夢姍.抗癲癇藥的致死性不良反應.中華神經科雜志, 2015, 48(12):1102-1105.
|
| 7. |
何曉靜, 肇麗梅.卡馬西平嚴重皮膚不良反應發病機制的研究進展.中國藥學雜志, 2012, 47(18):1462-1464.
|
| 8. |
Basta-Kaim A, Budziszewska B, Lason W.Effects of antiepileptic drugs on immune system.Przeg Lek, 2008, 65(11):799-802.
|
| 9. |
Ueta M, Sotozono C, Inatomi T, et al.HLA class Ⅰ and Ⅱ gene polymorphisms in Stevens-Johnson syndrome with ocular complications in japanese.Mol Vis, 2008, 14(3):550-555.
|
| 10. |
Kaniwa N, Saito Y, Aihara M, et al.HLA-B*1511 is a risk factor for carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in japanese patients.Epilepsia, 2010, 51(8):2461-2465.
|
| 11. |
Grover S, Kukreti R.HLA alleles and hypersensitivity to carbamazepine:an updated systematic review with meta-analysis.Pharmacogenetics and Genomics, 2014, 24(2):104-112.
|
| 12. |
Trivedi BS, Darji NH, Malhotra SD, et al.Antiepileptic drugs-induced stevens-johnson syndrome:a case series.J Basic Clin Pharm, 2016, 8(1):42-44.
|
| 13. |
王韋, 胡發云, 任潔釧, 等.左乙拉西坦所致輕度皮疹與HLA等位基因相關性研究.癲癇雜志, 2017, 3(2):121-125.
|
| 14. |
Saaiq M, Report Iqbal T.Fatal toxic epidermal necrolysis induced by sodium valproate.Pak J Pharm Sci, 2013, 26(3):637-639.
|
| 15. |
Handoko KB, van Puijenbroek EP, Bijl AH, et al.Influence of chemical structure on hypersensitivity reactions induced by antiepileptic drugs:the role of the aromatic ring.Drug Safety, 2008, 31(8):695-702.
|
| 16. |
Wang XQ, Lang SY, Shi XB, et al. Cross-reactivity of skin rashes with current antiepileptic drugs in Chinese population.Seizure, 2010, 19(9):562-566.
|
| 17. |
Hirsch LJ, Arif H, Nahm EA, et al.Cross-sensitivity of skin rashes with antiepileptic drug use.Neurology, 2008, 71(19):1527-1534.
|
| 18. |
Knowles SR, Dewhurst N, Shear NH.Anticonvulsant hypersensitivity syndrome:an update.Expert Opin Drug Saf, 2012, 11(5):767-778.
|
| 19. |
Borchers AT, Lee JL, Naguwa SM, et al.Stevens-Johnson syndrome and toxic epidermal necrolysis.Autoimmunity Reviews, 2008, 7(8):598-605.
|
| 20. |
Wong A, Malvestiti AA, Hafner Mde F.Stevens-Johnson syndrome and toxic epidermal necrolysis:a review.Rev Assoc Med Bras, 2016, 62(5):468-473.
|
| 21. |
Wang XQ, Xiong J, Xu WH, et al.Risk of a lamotrigine-related skin rash current meta-analysis and postmarketingcohort analysis.Seizure, 2015, 25(4):52-61.
|
| 22. |
Marzano AV, Borghi A, Cugno M.Adverse drug reactions and organ damage:the skin.Eur J Intern Med, 2016, 28(3):17-24.
|
| 23. |
Barton SJ, Del Vecchio MT, Aronoff SC. Intravenous immunoglobulin in the treatment of stevens.Johnson syndrome and toxic epidermal necrolysis:a meta-analysis with meta-regression of observational studies.Inl J Dermatol, 2015, 54(1):108-115.
|
| 24. |
Aihara M, Kano Y, Fujita H, et al.Efficacy of additional immunoglobulin to steroid therapy in Stevens-Johnson syndrome and toxic epidermal necrolysis.J Dermatol, 2015, 42(8):768-777.
|
